TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12714472
Drug: General practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner care (counselling, education, and drugs)
Study: 19508590
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion
Study: 22362401
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion
Study: 1572459
Drug: No detectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: No detectable serum concentration (less than 50 ng ml‐1)
Study: 26856320
Drug: Dexmedetomidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.8 μg/kg/h continuous infusion)
Study: 16325037
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day (F group)
Study: 9484961
Drug: Artemether (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (intramuscular injection)
Study: 9484961
Drug: Quinine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (intravenous infusion)
Study: 18617486
Drug: Oral co‐trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co‐trimoxazole
Study: 25885325
Drug: RTS,S/AS01E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E vaccine (0-1-2-month schedule)
Study: 9174388
Drug: PGE1 treatment
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 treatment (60 micrograms PGE1 in 250 ml of physiological saline, twice daily for 3 weeks)
Study: 1359619
Drug: AZT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT (300 mg/day) + ACV (600 mg/day)
Study: 6770673
Drug: Cefaclor (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (20 mg/kg/day for 10 days)
Study: 25095846
Drug: Kefir drink
Normalized name: Lentilactobacillus kefiri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir drink (100 ml per day for 2 weeks)
Study: 19962985
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose
Study: 22721966
Drug: Exendin(9-39) infusion
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin(9-39) infusion
Study: 9861862
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B surface antigen (HbsAg) and antibodies to hepatitis B virus (anti‐HBV)
Study: 2778791
Drug: lisinopril (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (20-40 mg once daily)
Study: 28832557
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care plus self‐efficacy interventions (health education, behavior therapy, psychological intervention)
Study: 19749494
Drug: efonidipine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Efonidipine (DB09235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: efonidipine hydrochloride ethanolate 40 mg/day
Study: 19749494
Drug: amlodipine besilate
Normalized name: Amlodipine besilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine besilate 5 mg/day
Study: 17093150
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Cuban sugar cane policosanol (SCP) per day
Study: 15055092
Drug: Placebo-magnetic knee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-magnetic knee sleeve treatment
Study: 8127283
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg for gastroscopy, 4 mg for colonoscopy)
Study: 21697747
Drug: Concurrent Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Training (CT)
Study: 25142085
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate hydration (1-h 250 mL 1.4%)
Study: 10981820
Drug: Pulsating magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsating magnetic field (induction: 25-80 microT; frequency: 200 Hz) applied for 3 weeks (5 days/week, twice a day for 8 minutes each)
Study: 8814695
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in disseminated disease (Ann Arbor stage III)
Study: 1706244
Drug: beta-hCG vaccine
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-hCG vaccine formulations
Study: 20935058
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of 0.25 mg palonosetron
Study: 20935058
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of 0.25 mg palonosetron
Study: 20935058
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of 0.25 mg palonosetron
Study: 19840579
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of clopidogrel for 30 days (group II)
Study: 16938749
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (intended INR 1.3-1.9)
Study: 9363869
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no warfarin)
Study: 18208828
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin
Study: 11990165
Drug: Albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administered via Rotahaler at various altitudes
Study: 31881995
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) specific for LLD, delivered in 15 sessions over 8 weeks (twice per week) with a 6-month follow-up period.
Study: 31881995
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) specific for LLD.
Study: 30387904
Drug: Pimavanserin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin with cognitive-enhancing medication
Study: 30387904
Drug: Pimavanserin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin without cognitive-enhancing medication
Study: 24121917
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (G1)
Study: 11340105
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral stimulation
Study: 9862944
Drug: Atovaquone (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (1500 mg daily)
Study: 1098594
Drug: Quinestrol 2
Normalized name: quinestrol
DrugBank: Quinestrol (DB04575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinestrol 2 mg
Study: 21723606
Drug: Linagliptin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 0.5 mg
Study: 21333984
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone
Study: 16490616
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/d plus ezetimibe 10 mg/d
Study: 10885234
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg.kg‐1 intravenous bolus injection followed by 6 mg.kg‐1.h‐1 infusion)
Study: 10885234
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg.kg‐1 intravenous bolus injection followed by 1 mg.kg‐1.h‐1 infusion)
Study: 10885234
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 micrograms.kg‐1 injection)
Study: 6441958
Drug: Vasopressin treatment
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin treatment
Study: 18653315
Drug: Carrot juice
Normalized name: carrot juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice (330 mL daily)
Study: 15504308
Drug: Rabeprazole (RAB)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RAB) 10 mg
Study: 23829508
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg)
Study: 29316931
Drug: Novel multi-component
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel multi-component fortifier and protein supplement derived from donkey milk
Study: 29316931
Drug: Control bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control bovine milk-based multicomponent fortifier and protein supplement
Study: 21206546
Drug: Ramelteon 8
Normalized name: ramelteon 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon 8 mg (n = 8)
Study: 8842657
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg kg‐1 i.v. bolus, followed by continuous infusion (15 patients)
Study: 6130295
Drug: Red-cell suspension
Normalized name: RED CELL TAGGING KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red-cell suspension in SAGM medium
Study: 31727361
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg combined with rosuvastatin 5 mg (R5 + E10)
Study: 31727361
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg combined with Ezetimibe 10 mg (R10 + E10)
Study: 25847819
Drug: 3-dimensional conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dimensional conformal radiation therapy (3D-CRT)
Study: 24346989
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
Study: 7128838
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 6 months
Study: 21304215
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg combined with ezetimibe 10 mg (F20/E10)
Study: 7489937
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg daily
Study: 8071301
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with clinician's choice, including continued phenelzine and combination with amitriptyline
Study: 8071301
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with clinician's choice, including a variety of other treatments
Study: 3189898
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 1 mg
Study: 7008655
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 2 mg
Study: 3377948
Drug: i.v. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine 30 mg
Study: 25735497
Drug: Ramosetron 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.6 mg mixed with PCA (RPCA group)
Study: 25735497
Drug: Palonosetron 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 75 μg (P group)
Study: 25735497
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg (R0.3 group)
Study: 21705068
Drug: Diet intervention
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet intervention (dietary consultation every 3 months with monthly nurse support)
Study: 21705068
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus activity intervention (dietary consultation every 3 months with monthly nurse support plus a pedometer-based activity programme)
Study: 16981967
Drug: Once-daily urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily urokinase (5000-6000 IU/kg/dose)
Study: 8281243
Drug: Fluoxetine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (80 mg/day)
Study: 9286186
Drug: Phenelzine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (60 mg/day)
Study: 8139135
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (rHuEPO) at doses of 3,000 and 6,000 IU, administered once per week for 8 weeks.
Study: 2761587
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg daily)
Study: 20868461
Drug: Family‐Focused Treatment‐Health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐Focused Treatment‐Health Promoting Intervention (FFT‐HPI)
Study: 17219034
Drug: Ropinirole at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole at 15 mg per day
Study: 17219034
Drug: Pramipexole at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole at 2.1 mg per day
Study: 11106918
Drug: octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: octreotide LAR 20 mg once monthly for three months
Study: 8842608
Drug: Hyperglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (blood glucose 15.7 +/‐ 0.48 mmol/l)
Study: 8842608
Drug: Euglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (blood glucose 5.1 +/‐ 0.04 mmol/l)
Study: 31520149
Drug: Psycho-educational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational group therapy module (STEM) with 8 sessions plus 3 sessions on stigma coping and empowerment
Study: 31520149
Drug: Standard psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychoeducational group therapy extended to 11 sessions plus 1 booster session
Study: 31520149
Drug: Psycho-educational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational group therapy module (STEM)
Study: 31520149
Drug: Standard psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychoeducational group therapy
Study: 27706464
Drug: High-flow conditioned
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow conditioned oxygen therapy
Study: 21178076
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400 mg daily)
Study: 580217
Drug: 1‐(m‐methoxyphenyl)‐2‐(dimethylaminomethyl)‐cyclohexan‐1‐ol (tramadol;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐(m‐methoxyphenyl)‐2‐(dimethylaminomethyl)‐cyclohexan‐1‐ol (tramadol; Tramal) 100 mg i.m.
Study: 19955857
Drug: LAT patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT patients without warfarin
Study: 9383499
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg tablets/2 mg oral dose)
Study: 8042069
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course treatment
Study: 28148473
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation methods
Study: 23338056
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 0.25% levobupivacaine 0.5 ml kg(‐1)
Study: 23338056
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 0.2 ml kg(‐1) 0.25% levobupivacaine
Study: 10714908
Drug: E2-DSG (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2-DSG (1.5 mg E2 for 24 days with 0.15 mg DSG for the last 12 days followed by a placebo tablet for 4 days)
Study: 10714908
Drug: E2V-MPA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2V-MPA (2 mg E2V for 21 days with 10 mg MPA for the last 10 days)
Study: 10350027
Drug: Haloperidol 4
Normalized name: haloperidol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 4 mg
Study: 9361328
Drug: Haloperidol 6
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 6 mg
Study: 2942494
Drug: Lorazepam 2.5
Normalized name: lorazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2.5 mg
Study: 24883319
Drug: Ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine + Tramadol (50 mg)
Study: 24883319
Drug: Ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine + Ketamine (50 mg)
Study: 20071289
Drug: CIPRO XR
Normalized name: Cipro XR
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIPRO XR 1000 mg once daily
Study: 20071289
Drug: CIPRO IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPRO IR 500 mg twice daily
Study: 16459272
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg IV over 2 min) + Naloxone (0.1 ng/kg)
Study: 18694635
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 300 mg/day WS 5570
Study: 11345689
Drug: Salicis cortex
Normalized name: Salicis cortex
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicis cortex extract with 240 mg salicin/day
Study: 11345689
Drug: Acetylsalicylate 100
Normalized name: Acetylsalicylate
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylate 100 mg/day
Study: 8025207
Drug: Glipizide plus
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide plus intensive insulin treatment (Group B)
Study: 10390663
Drug: Midazolam (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5-7.5 mg)
Study: 3631495
Drug: Meperidine (50-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (50-75 mg) and Promethazine (25-50 mg)
Study: 31802733
Drug: Combined arms
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined arms of villages that received four rounds of treatment
Study: 31802733
Drug: School-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based treatment (SBT) for first-year primary students and adults
Study: 31684847
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) under level 1A evidence
Study: 31684847
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) under level 2B evidence
Study: 26720025
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus triptorelin (LHRHa group)
Study: 17253878
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) with serotonergic properties (e.g., carbamazepine, oxcarbazepine, valproate, lamotrigine)
Study: 17253878
Drug: Other AEDs
Normalized name: Bisphenol A diglycidyl ether
DrugBank: Bisphenol A diglycidyl ether (DB14083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other AEDs (e.g., topiramate, tiagabine, vigabatrin, levetiracetam, zonisamide)
Study: 11573114
Drug: Sulphadoxine/Pyrimethamine (1500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine/Pyrimethamine (1500mg sulphadoxine and 75mg pyrimethamine as a single dose)
Study: 11573114
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Sulphadoxine/Pyrimethamine and Doxycycline
Study: 30352668
Drug: Integrated Dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Dual Diagnosis Treatment (IDDT)
Study: 26025097
Drug: Intravitreal Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Aflibercept Injection (IAI) 2 mg every 4 weeks (2q4)
Study: 19055281
Drug: Warming needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming needle therapy
Study: 14739418
Drug: Aphasia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aphasia therapy
Study: 8273399
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose betamethasone (8 mg/2 days)
Study: 3034062
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (25, 50, 100, or 200 micrograms/day)
Study: 3034062
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 micrograms patch)
Study: 3034062
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg and 1.25 mg)
Study: 24750838
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/(m(2)·d), Qd) for 6 months
Study: 23803270
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) for 20 minutes
Study: 16550737
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg) from Laboratórios Cristália Ltd.
Study: 16550737
Drug: Cozaar (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cozaar (50 mg) from Merck Sharp & Dohme Farmacêutica Ltd.
Study: 12093324
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg/day)
Study: 10819825
Drug: 3‐day diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐day diet containing at least 150 g carbohydrate per day
Study: 1363488
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl (2 micrograms/kg) and vecuronium (120 micrograms/kg)
Study: 1363488
Drug: Propofol (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (induction agent)
Study: 6585733
Drug: 3-mg prostaglandin
Normalized name: PROSTAGLANDINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg prostaglandin E2 (PGE2) vaginal suppository
Study: 31733777
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment combined with core muscle strengthening exercises (Experimental Group)
Study: 31733777
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (Control Group)
Study: 12381038
Drug: Imaginal exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaginal exposure therapy (IET)